BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1848196)

  • 1. In vivo somatostatin receptor imaging in the detection and treatment of gastrointestinal cancer.
    Schubert ML
    Gastroenterology; 1991 Apr; 100(4):1143-4. PubMed ID: 1848196
    [No Abstract]   [Full Text] [Related]  

  • 2. Somatostatin-receptor imaging for the detection of tumors.
    Patel YC
    N Engl J Med; 1990 Nov; 323(18):1274-6. PubMed ID: 2170841
    [No Abstract]   [Full Text] [Related]  

  • 3. Somatostatin-receptor imaging in the localization of endocrine tumors.
    Lamberts SW; Bakker WH; Reubi JC; Krenning EP
    N Engl J Med; 1990 Nov; 323(18):1246-9. PubMed ID: 2170840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A new imaging procedure for detecting endocrine tumors].
    Schäffer M; Fölsch UR
    Z Gastroenterol; 1991 Apr; 29(4):173-4. PubMed ID: 1651031
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment with Sandostatin and in vivo localization of tumors with radiolabeled somatostatin analogs.
    Lamberts SW; Bakker WH; Reubi JC; Krenning EP
    Metabolism; 1990 Sep; 39(9 Suppl 2):152-5. PubMed ID: 2169572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of somatostatin receptor scintigraphy in the localization of neuroendocrine tumors.
    Lamberts SW; Reubi JC; Krenning EP
    Acta Oncol; 1993; 32(2):167-70. PubMed ID: 8391830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new diagnostic method: somatostatin receptor scintigraphy of neuroendocrine tumors].
    Westlin JE; Janson ET; Ahlström H; Ohrvall U; Arnberg H; Nilsson S; Akerström G; Oberg K
    Lakartidningen; 1992 Dec; 89(50):4377-9. PubMed ID: 1469974
    [No Abstract]   [Full Text] [Related]  

  • 8. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
    Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of radiolabeled somatostatin analogs in the identification and treatment of somatostatin receptor-bearing tumors.
    Hurst RD; Modlin IM
    Digestion; 1993; 54 Suppl 1():88-91. PubMed ID: 8359574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors.
    van Eyck CH; Bruining HA; Reubi JC; Bakker WH; Oei HY; Krenning EP; Lamberts SW
    World J Surg; 1993; 17(4):444-7. PubMed ID: 8395748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas.
    Becker W; Marienhagen J; Scheubel R; Saptogino A; Bakker WH; Breeman WA; Wolf F
    Eur J Nucl Med; 1991; 18(11):924-7. PubMed ID: 1684323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
    Reubi JC; Kvols LK; Waser B; Nagorney DM; Heitz PU; Charboneau JW; Reading CC; Moertel C
    Cancer Res; 1990 Sep; 50(18):5969-77. PubMed ID: 2168286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.
    Kvols LK; Brown ML; O'Connor MK; Hung JC; Hayostek RJ; Reubi JC; Lamberts SW
    Radiology; 1993 Apr; 187(1):129-33. PubMed ID: 8383865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Somatostatin receptor scintigraphy. Methodology, indications, results].
    Eising EG; Bier D; Knust EJ; Reiners C
    Radiologe; 1996 Jan; 36(1):81-8. PubMed ID: 8820376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
    Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
    Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical application of somatostatin receptor imaging.
    Reichlin S
    J Clin Endocrinol Metab; 1990 Sep; 71(3):564-5. PubMed ID: 2168429
    [No Abstract]   [Full Text] [Related]  

  • 20. 68Ga-DOTA-NOC PET and peptide receptor radionuclide therapy in management of bilateral ovarian metastases from gastrointestinal carcinoid.
    Singla S; Gupta S; Reddy RM; Durgapal P; Bal CS
    Jpn J Clin Oncol; 2012 Dec; 42(12):1202-6. PubMed ID: 23107835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.